Short Interest in Novavax, Inc. (NVAX) Expands By 3.1%

Novavax, Inc. (NASDAQ:NVAX) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 43,348,136 shares, a growth of 3.1% from the November 30th total of 42,042,156 shares. Currently, 14.0% of the company’s shares are sold short. Based on an average daily volume of 6,022,377 shares, the days-to-cover ratio is currently 7.2 days.

Shares of Novavax (NASDAQ:NVAX) opened at $1.35 on Thursday. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28. The stock has a market capitalization of $423.38, a price-to-earnings ratio of -1.99 and a beta of 2.03. Novavax has a 52-week low of $0.73 and a 52-week high of $1.78.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.01. The business had revenue of $8.35 million during the quarter, compared to analyst estimates of $6.42 million. The firm’s revenue for the quarter was up 158.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.24) EPS. equities research analysts forecast that Novavax will post -0.62 earnings per share for the current fiscal year.

In other news, insider Stanley C. Erck acquired 100,000 shares of Novavax stock in a transaction on Thursday, November 9th. The shares were bought at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the acquisition, the insider now directly owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of NVAX. Raymond James Financial Services Advisors Inc. boosted its position in shares of Novavax by 49.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 29,800 shares in the last quarter. Profund Advisors LLC boosted its position in shares of Novavax by 0.4% in the 2nd quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 455 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Novavax by 18.6% in the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 21,639 shares in the last quarter. Brown Advisory Inc. boosted its position in shares of Novavax by 74.8% in the 3rd quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 69,600 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Novavax in the 2nd quarter worth $230,000. 36.78% of the stock is owned by hedge funds and other institutional investors.

Several analysts have issued reports on the company. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 target price on shares of Novavax in a research report on Wednesday, November 8th. Citigroup cut Novavax from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Tuesday, December 19th. Seaport Global Securities reaffirmed a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Finally, Zacks Investment Research cut Novavax from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Novavax has a consensus rating of “Hold” and an average target price of $2.98.

ILLEGAL ACTIVITY WARNING: “Short Interest in Novavax, Inc. (NVAX) Expands By 3.1%” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/04/short-interest-in-novavax-inc-nvax-expands-by-3-1.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply